Professional
Added to YB: 2025-02-25
Pitch date: 2025-01-15
EW [bullish]
Edwards Lifesciences Corporation
+20.49%
current return
Author Info
No bio for this author
Company Info
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
Market Cap
$50.0B
Pitch Price
$68.95
Price Target
N/A
Dividend
N/A
EV/EBITDA
25.79
P/E
37.70
EV/Sales
7.97
Sector
Health Care Equipment and Supplies
Category
growth
Wedgewood Partners Portfolio Holding: Edwards Lifesciences Corporation
EW: TAVR market maturing but not saturated. EARLY TAVR trial: 45% of untreated asymptomatic aortic stenosis patients died/suffered stroke/hospitalized vs 26% treated. Study positions aortic stenosis treatment like cancer. Double-digit earnings growth expected as structural heart franchise expands.
Read full article (1 min)